Response to the Letter to the Editor on "γ-Secretase modulation and plaque regression in Alzheimer's disease"
Gunnar Nordvall1, Ping Yan2, Lotta Agholme3
1AlzeCure Pharma AB, Huddinge, Sweden; Former AstraZeneca R&D, CNS & Pain Innovative Medicines, Södertälje, Sweden; Division of Neurogeriatrics, Care Sciences and Society, Department of Neurobiology, Karolinska Institutet, Solna, Sweden.
The Journal of Pharmacology and Experimental Therapeutics
|September 26, 2025
Abstract
No abstract available in PubMed .
More Related Videos
Related Concept Videos
01:22Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K